ArQule, Inc. and Daiichi Sankyo, Co., Ltd.
Positive Phase 2 Clinical Data With Tivantinib in Hepatocellular Carcinoma to be Highlighted in Oral Presentation at 2012 Annual Meeting of American Society of Clinical Oncology
Woburn, Massachusetts And Tokyo (ots/PRNewswire) - ArQule, Inc. and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line ...
mehr